Navigating Genetic Influences on the Topography of Alzheimer’s Disease
Sign Up to like & getrecommendations! Published in 2018 at "Biological Psychiatry"
DOI: 10.1016/j.biopsych.2018.07.012
Abstract: JMS has received research funding and PET tracer from AVID Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly); has consulted for Roche, Eli Lilly, Biogen and Merck; received royalties from Oxford University Press and Henry… read more here.
Keywords: topography; influences topography; genetic influences; navigating genetic ... See more keywords
A cross‐sectional study of psoriasis triggers among different ethno‐racial groups
Sign Up to like & getrecommendations! Published in 2017 at "Journal of the American Academy of Dermatology"
DOI: 10.1016/j.jaad.2017.04.1109
Abstract: Dr Bissonnette has received grants and research support, served as a consultant or received honoria from AbbVie, Amgen, Apopharma, Boehringer Ingelheim, Celgene, Dermira, Eli Lilly, Galderma, GSK-Stiefel, Merck, Incyte, Janssen, Kineta, Leo Pharma, Merck, Novartis,… read more here.
Keywords: leo pharma; eli lilly; celgene; merck ... See more keywords
Erratum to "Analysing UK clinicians' understanding of cognitive symptoms in major depression: A survey of primary care physicians and psychiatrists" [J. Affect. Disord. 207 (2017) 346-352].
Sign Up to like & getrecommendations! Published in 2017 at "Journal of affective disorders"
DOI: 10.1016/j.jad.2017.04.023
Abstract: The publisher regrets the omission of the following Acknowledgements, Role of funding source and Conflict of interest information in the original publication. RHMW, KB, GMG, JH, CK, JR, SS and AHY contributed as authors on… read more here.
Keywords: received payment; research; lundbeck; eli lilly ... See more keywords
146. Intact Sense of Taste and Smell During COVID-19 Infection Is Associated with Absence of of SARS-CoV-2 Spike Protein Antibody Responses within 3 Months of Symptomatic Illness
Sign Up to like & getrecommendations! Published in 2021 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofab466.146
Abstract: Abstract Background Although studies show most COVID-19 survivors have post-infection immunity against SARS-CoV-2 that could prevent re-infection, there is still a need to identify the breadth of antibody (Ab) responses associated with clinical phenotypes. We… read more here.
Keywords: sars cov; eli lilly; antibody; infection ... See more keywords
P204 Effect of baricitinib on functional impairment in RA patients with moderate disease activity and an inadequate response to conventional DMARDs
Sign Up to like & getrecommendations! Published in 2020 at "Rheumatology"
DOI: 10.1093/rheumatology/keaa111.199
Abstract: In RA, disease activity correlates with physical function and there is a link between joint damage and functional disability. In many countries, RA patients with inadequate response (IR) to MTX or other conventional DMARDs (cDMARDs)… read more here.
Keywords: eli lilly; disease activity; treatment; bari ... See more keywords
P193 Clinical features of patients with active ankylosing spondylitis who did not respond to adalimumab but responded to ixekizumab: a post-hoc analysis
Sign Up to like & getrecommendations! Published in 2021 at "Rheumatology"
DOI: 10.1093/rheumatology/keab247.188
Abstract: Background/Aims Biologic treatment in ankylosing spondylitis (AS) are currently limited to TNF and IL-17A inhibitors (IL-17Ai). It is unknown whether there are predictors of AS patients who only respond to 1 of these mechanisms of… read more here.
Keywords: ixe; eli lilly; novartis; shareholder ... See more keywords
OA14 Non-steroidal anti-inflammatory drugs reduce sacroiliac joint inflammation in axial spondyloarthritis
Sign Up to like & getrecommendations! Published in 2023 at "Rheumatology"
DOI: 10.1093/rheumatology/kead104.014
Abstract: MRI evidence of active sacroiliitis (sacroiliac joint bone marrow oedema (BMO)) is commonly used to assist diagnosis and classification of axial spondyloarthritis (axSpA). Non-steroidal anti-inflammatory drugs (NSAIDs) are used as first-line therapy, and for persistent… read more here.
Keywords: rheumatology; novartis pfizer; sacroiliac joint; pfizer ... See more keywords
P107 Long-term efficacy of baricitinib in patients with rheumatoid arthritis with inadequate response to bDMARDs: results from RA-BEYOND up to 6.9-years of treatment
Sign Up to like & getrecommendations! Published in 2023 at "Rheumatology"
DOI: 10.1093/rheumatology/kead104.148
Abstract: Baricitinib (BARI), an oral selective Janus kinase 1/2 inhibitor, is approved for treatment of adults with moderately-to-severely active rheumatoid arthritis (RA). BARI demonstrated efficacy in patients (pts) with RA who have inadequate response to biologic… read more here.
Keywords: research; efficacy; eli lilly; bari ... See more keywords
P127 Baricitinib Efficacy in Moderate Rheumatoid Arthritis - A Post-hoc Analysis from two Phase III Trials
Sign Up to like & getrecommendations! Published in 2023 at "Rheumatology"
DOI: 10.1093/rheumatology/kead104.168
Abstract: Baricitinib, an oral selective JAK 1/2 inhibitor, is approved for treating adults with moderate-to-severe active rheumatoid arthritis (RA). This analysis aims to report the efficacy of baricitinib in patients with moderate RA at weeks (W)12… read more here.
Keywords: lilly company; analysis; eli lilly; research support ... See more keywords
P128 Long-term safety and efficacy of upadacitinib in patients with rheumatoid arthritis: final results from the BALANCE-EXTEND open-label extension study
Sign Up to like & getrecommendations! Published in 2023 at "Rheumatology"
DOI: 10.1093/rheumatology/kead104.169
Abstract: Upadacitinib (UPA) was previously evaluated in two Phase 2, randomized, controlled trials (RCTs) in patients (pts) with rheumatoid arthritis (RA) and inadequate response to tumor necrosis factor inhibitors (BALANCE-1) or methotrexate (BALANCE-2). Objectives: To assess… read more here.
Keywords: safety; bid; efficacy; eli lilly ... See more keywords
P131 Time to Discontinuation and Effectiveness with Baricitinib in Rheumatoid Arthritis: 12-Month European Data from a Multinational, Prospective, Observational Study
Sign Up to like & getrecommendations! Published in 2023 at "Rheumatology"
DOI: 10.1093/rheumatology/kead104.172
Abstract: RA-BE-REAL is a 3-year, multinational, prospective, observational study of adult patients with rheumatoid arthritis (RA) evaluating time-to-discontinuation of initial RA treatment. Baricitinib (BARI), an oral selective JAK1/2 inhibitor, is approved for the treatment of adults… read more here.
Keywords: time; lilly company; eli lilly; discontinuation ... See more keywords